Angelini Pharma, a historic Italian family-owned company, has announced a $4.1 billion agreement to acquire Florida-based Catalyst Pharmaceuticals. This marks the largest acquisition in Angelini’s 107-year history, providing a major entry point and scale into the world’s largest pharmaceutical market.
Transaction details and financial structure
-
Offer price: Angelini is paying $31.50 per share for Catalyst, a 21% premium over the share price prior to market rumors of the buyout.
-
Funding: The Italian public development bank, CDP Equity, is helping to fund the deal by taking a minority stake in Angelini.
-
Closing timeline: The companies expect to close the transaction in the third quarter of 2026.
Acquiring a high-value rare disease portfolio Through Catalyst, Angelini gains control over several key therapies:
-
Firdapse: A potential blockbuster treatment for Lambert-Eaton myasthenic syndrome (LEMS), which generated $358 million in sales in 2025. It is considered the core asset for Angelini’s U.S. expansion.
-
Agamree: A treatment for Duchenne muscular dystrophy (partnered with Santhera), which racked up $117 million in U.S. sales last year.
-
Fycompa: A seizure medication that, while facing recent generic competition, continues to contribute significantly to the company’s revenue.
Strategic “globalization” of Italian Pharma This deal follows closely on the heels of another Italian private drugmaker, Chiesi, acquiring Massachusetts-based KalVista for $1.9 billion. This underscores a strong trend among Italian private pharmaceutical groups transforming from regional players into global competitors, particularly in rare diseases and neurology.
Angelini’s leadership emphasized that entering the U.S. market is not just about gaining scale, but a strategic move to acquire the scientific and organizational capabilities needed to compete at the highest global level.
Source: https://www.fiercepharma.com/pharma/angelini-finds-catalyst-its-us-growth-ambitions-41b-buyout